Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Belzutifan for vHL Associated Tumors
Single-arm, phase 2 trial (LITESPARK-004) VHL disease patients with RCC, CNS hemangioblastomas, or pancreatic NETs Belzutifan 120 mg orally once daily
New Protocol: Atezolizumab with Carbo-Pem-Bev for Pleural Mesothelioma
Randomized, open-label, phase 3 trial (BEAT-meso) Unresectable, untreated pleural mesothelioma patients Atezolizumab + cisplatin + pemetrexed + bevacizumab (Atezo-CPB) vs. cisplati
New Protocol: Atezolizumab and Trastuzumab with CapeOx for Periop Her2+ Gastric Cancer
Open-label, randomized, phase 2 trial (NCT04661150) Resectable, HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma Atezolizumab + trastuzumab + XELOX (arm A)
New Reference: Acalabrutinib with R-Bendamustine in Untreated Mantle Cell Lymphoma
Randomized, double-blind, phase 3 trial (ECHO, NCT02972840) Previously untreated mantle cell lymphoma patients ≥65 years Acalabrutinib + bendamustine + rituximab (ABR) vs. placeb
New Reference: Taletrectinib for ROS1-Positive NSCLC
Phase 2, open-label, single-arm, multicenter trials (TRUST-I and TRUST-II) ROS1-positive advanced or metastatic NSCLC Taletrectinib 600 mg once daily
New Protocol: Regorafenib Maintenance for Sarcoma
Double-blind, placebo-controlled, randomized phase 2 trial (EREMISS) Advanced non-adipocytic soft tissue sarcomas post 1st-line doxorubicin-based chemotherapy Regorafenib 120 mg/da
New Indication: Nivolumab – Ipilimumab for Neoadjuvant NSCLC
Phase 3, randomized, open-label trial (CheckMate 816) Stage IB-IIIA resectable NSCLC Neoadjuvant nivolumab + ipilimumab vs. chemotherapy
New Protocol: Eribulin with Trastuzumab-Pertuzumab in First-Line Breast Cancer
Phase 3, randomized, open-label, noninferiority trial (EMERALD) HER2+ locally advanced/metastatic breast cancer Eribulin + trastuzumab + pertuzumab vs. Taxane (docetaxel or paclita
